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Advances in positron emission tomography (PET) techniques have allowed the measurement and imaging of serotonin synthesis,
transport and receptor binding in the living human brain. 
Both the imaging and pathological studies in patients with epilepsy, as well as studies derived from experimental models of epilepsy
provide evidence that endogenous serotonin plays a significant role in epileptogenesis. This review summarizes the advances in alpha-
Methyl tryptophan PET imaging in patients with different types of epilepsy.
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INTRODUCTION
Epilepsy is a heterogeneous group of disorders of various etiolo-
gies characterized by recurrent, usually spontaneous paroxysmal
clinical events known as epileptic seizures. Epileptic seizures are
signs and symptoms of cerebral dysfunction, resulting from
paroxysmal hyperexcitable or hypersynchronous discharges of
neurons involving predominantly the cerebral cortex. Data
derived from experimental models of epilepsy indicate that tar-
geting serotonin synthesis may provide important clinical and
pathophysiological clues. The development of new probes for
positron emission tomography (PET) in epilepsy has the poten-
tial to improve the identification of the epileptogenic focus for
clinical purposes and to advance our understanding of the neuro-
chemical processes underlying epilepsy. 
The serotonergic system
In the human brain, the serotonergic system originates from the
raphe nuclei that give widespread projections to all areas of the
central nervous system (2). In keeping with its diffuse anatomi-
cal distribution, serotonin seems to modulate different functions
and it has been implicated in a variety of neurological disorders,
including epilepsy. This has prompted the development of nonin-
vasive methods for studying the serotonergic system in the living
human brain. Various approaches have been proposed, targeting
different aspects of serotonergic transmission such as the 5-HT1A
and 5-HT2A receptors (18,22,28), the serotonin transporters (43)
and the serotonin vesicular uptake sites (6). Among these meth-
ods is the measurement of serotonin synthesis which estimates
the activity of the presynaptic serotonergic transmission (3).
Regulation of serotonin synthesis
Serotonin is synthesized from the neutral amino acid L-trypto-
phan which is hydroxylated to 5-hydroxytryptophan and then
rapidly decarboxylated to serotonin. The first of these reactions
is catalyzed by the enzyme tryptophan hydroxylase (TPH) which
is restricted to serotonergic neurons (29). TPH utilizes two sub-
strates, L-tryptophan and molecular oxygen, as well a reduced
pterin as an electron donor. In physiological conditions, TPH is
not saturated by any of its substrates (3). As a consequence, an
increase in their concentration will lead to an increase in sero-
tonin synthesis. Such an effect has been demonstrated in several
species for tetrabiopterin (34); oxygen (11,14,38); and trypto-
phan (5,14,52). Similarly a reduction in the body and presumably
brain tryptophan results in a decrease in the brain serotonin syn-
thesis (39). Serotonin synthesis can also be influenced by neu-
ronal firing. Electrical stimulation of the dorsal raphe over the
range of frequencies at which serotonin are known to fire (2-20
Hz) increases the level of serotonin in the dialysate. Although the
mechanism underlying this process is unknown, it has been pos-
tulated that neuronal firing increases Vmax of TPH (4) and
enhances tryptophan uptake into serotonergic neurons (12). 
Alpha-methyl tryptophan as a tracer of serotonin synthesis
Alpha-methyl tryptophan ("-MTrp) is an artificial amino acid
and analogue of tryptophan (45). The ligand reflects the uptake
of tryptophan into the brain and in physiological conditions it is
thought to relate to the synthesis of serotonin (15). Several lines
of evidence support the validity of "-MTrp as a tracer for meas-
uring the rate of serotonin synthesis. First, labeled "-MTrp is
found at high tracer concentrations in serotonergic cell bodies of
the raphe nuclei and at an ultrastructural level it co-localizes with
TPH and endogenous serotonin in the perykaria and dendrites of
the raphe nuclei as well as in the axon terminals of the serotonin
target zones such as the cerebral cortex (9,15,33). Second,
labeled "-MTrp follows the serotonin biosynthetic pathway and
leads to the formation of "-Methyl-serotonin ("-M-5HT) which
is trapped irreversibly into the serotonergic neuron (9,13,15).
Third, labeled "-MTrp uptake is consistently affected by drugs
Marco Fedi and co-authors: Alpha [11C] Methyl-L-Tryptophan Positron Emission Tomography In Epilepsy
Med Vjesn 2007; 39(1-4): 31-34
32
that affect serotonin synthesis (i.e. the TPH inhibitors or 5HT1A
agonist) (39,49); or serotonin release and reuptake (35,40,47,51).
Finally, changes in plasma tryptophan and an increase in oxygen
saturation correlate well with the rate of the "-MTrp trapping
(14, 39). 
Two major critiques have been raised. The first is that the trap-
ping of the labeled "-MTrp relates to tryptophan incorporation
into proteins and that only its conversion to metabolite can be uti-
lized in the calculation of serotonin synthesis (21). Several stud-
ies have previously shown that "-MTrp is not incorporated into
proteins (16,32) and that its uptake is not affected by the protein
synthesis inhibitor cycloheximide (49). In addition, the unidirec-
tional uptake of "-MTrp does not correlate with the permeability
surface area product of tryptophan or tryptophan incorporation
into proteins (17). The second criticism arose from the observa-
tion that in anesthetized monkeys only a small proportion of
labeled "-MTrp is converted into "-M-5HT at 180 min post-
injection, suggesting that trapping is only a measure of the brain
uptake of tryptophan (44). It is important to emphasize that the "-
MTrp model is based on the brain tissue trapping of labeled "-
MTrp and not necessarily on its conversion to a metabolite. The
trapping constant is highly correlated to the conversion of trypto-
phan into serotonin but not with the tryptophan incorporation
into proteins (31). Furthermore, both rat and human tissue time
activity are fitted by an irreversible three-compartment model
rather than a two-compartment model (13), suggesting that "-
MTrp does not trace just the tryptophan transport from the plas-
ma into the brain rather it traces tryptophan conversion into sero-
tonin (17).
In physiological conditions, measurement of the unidirectional
uptake of "-MTrp is a valid approach for the determination of
brain serotonin synthesis rates (13). However, in pathological
conditions where inflammatory processes occur, the induction of
the indolamine 2,3-dioxygenase results in the synthesis from L-
tryptophan of metabolites of the kynurenine pathway (54). 
Serotonin in epilepsy
Studies in experimental models of epilepsy have suggested an
inhibitory role of serotonin on epileptiform discharges
(37,46,53). Electrical stimulation of the raphe nuclei increases
the release of serotonin and inhibits kindled amygdaloid seizures
(30). High frequency epileptiform discharges induce an increase
of microdyalisate levels of serotonin in rats treated with 4-
aminopyridine (27). In contrast, the inhibition of serotonin syn-
thesis by irreversible TPH inhibitors or depletion of forebrain
serotonin by lesions of the midbrain raphe increase seizure sus-
ceptibility (29). In human tissue, enhanced serotonergic innerva-
tion in the epileptogenic area of patients with cortical dysplasia
has been described (50). In addition, increased levels of serotonin
and of its metabolite 5-hydroxyindole acetic acid (5-HIAA) have
also been reported in epileptogenic lesions resected for seizure
control (41). 
"-[11C]-MTrp PET in patients with intractable epilepsy and cor-
tical dysplasia
Several studies have demonstrated that "-MTrp is able to identi-
fy regions of cortical dysgenesis with high specificity (19,24,25).
In our series, 7 patients with cortical dysplasia were studied, 57%
of which showed a focal increase of "-MTrp uptake within the
epileptic focus defined by ictal scalp EEG and MRI (19). The
sensitivity of "-[11C]-MTrp PET, in terms of lobar localization
has been reported to be lower than [18F]-fluorodeoxyglucose
(FDG) PET. However, the regions of reduced metabolism on
[18F]-FDG PET are widespread and extend beyond the structural
abnormality. In contrast, the increased uptake of "-[11C]-MTrp
PET has been demonstrated to be highly co-localized to the area
of neocortical seizure onset defined on electrocorticography (24).
Furthermore, in those patients with histologically proven cortical
dysplasia, the occurrence of increased "-MTrp uptake was high-
er compared to those with non-specific pathological changes (i.e.
gliosis) (24). This high specificity provides the opportunity to use
"-[11C]-MTrp PET to re-evaluate patients who underwent epilep-
sy surgery for further resections (25).
"-[11C]-MTrp PET in patients with intractable epilepsy and
tuberous sclerosis 
Several studies have demonstrated the unique ability of "-[11C]-
MTrp PET to successfully identify the epileptogenic area among
multiple dysplastic lesions in patients with tuberous sclerosis
(1,7,20,26). Initial studies showed that "-MTrp differentiated
between epileptogenic and nonepileptogenic tubers in about 2/3
of the patients (7). In our series, we studied 8 patients, 50% of
which showed focal increased uptake of "-MTrp in the epilepto-
genic area (20). The main advantage of "-MTrp is to show local-
ly increased uptake in and around the epileptogenic tuber, while
showing normal or decreased uptake in non-epileptogenic tubers
(1,20). We observed a correlation between focal increases in "-
MTrp uptake and interictal spike frequency, suggesting that
increased "-MTrp uptake relates to epileptogenicity (20). These
findings are not related to nonspecific changes in perfusion or
metabolism as indicated by a lack of changes in interictal mark-
ers of blood flow such as [15O]-H2O or with markers of metabo-
lism such as [18F]-FDG (20). However, the relationship between
a-MTrp uptake and interictal spike frequency has not been con-
firmed by other studies (24). 
It has been postulated that the mechanism of increased uptake of
"-MTrp in the epileptogenic tuber may be related to the synthe-
sis, from L-tryptophan, of quinolinic acid and other metabolites
of the kynurenine pathway. Local application of quinolinic acid
induces epileptiform discharges (48). Conversely, there is evi-
dence to suggest that NMDA antagonists can suppress hyperex-
citability in vivo and exert anticonvulsant effects in several ani-
mal models of epilepsy (10). Studies on the regional distribution
of tryptophan and its metabolites in the genetically epilepsy-
prone rat model of partial epilepsy have shown a significant
increase of kynurenine, serotonin and 5-HIAA in the cortex. Fur-
thermore, high levels of quinolinic acid and low levels of TPH in
epileptogenic dysplastic tissue with increased "-MTrp uptake on
PET have been described suggesting that in at least some cases,
increased "-MTrp uptake is mainly due to enhanced kynurenine
metabolism (8). However, in a human brain tissue study, no dif-
ferences were found in the concentrations of quinolinic acid
between epileptognic and non-epileptogenic regions and the
cerebrospinal fluid concentrations of quinolinic acid were signif-
icantly lower in patients than in controls (23).
"-[11C]-MTrp PET in non-lesional (cryptogenic) focal epilepsy
Patients with no detectable lesion on MRI present a difficult
problem in localization and usually have the least favorable sur-
gical outcome. Increased focal uptake of "-MTrp in a proportion
of such patients is a valuable addition to current methods of
investigation. In our study, we reported that 3 of 11 (27%)
patients with no detectable lesion on MRI showed focal
increased uptake of "-MTrp correlating with the ictal EEG find-
ings (19). It appears that "-[11C]-MTrp PET has a lower sensitiv-
ity for the localization and lateralization of epileptic foci in
patients with crytpogenic focal epilepsy. 
"-[11C]-MTrp PET in mesial temporal lobe epilepsy
Increased "-MTrp uptake has been described in 7 patients with
mesial temporal lobe epilepsy with normal hippocampal vol-
umes. In contrast, "-[11C]-MTrp PET in patients with hippocam-
pal atrophy failed to show changes in "-MTrp uptake (36). It is
possible that partial volume effects limit the accuracy of "-MTrp
PET imaging in the latter setting. The increased "-MTrp uptake
in patients with temporal lobe epilepsy might be related to aug-
mented neurogenesis. Recently, increased cell proliferation in the
dentate gyrus of adult rats via a 5HT1A receptor dependent
mechanism has been reported in the pilocarpine model of epilep-
sy (42).
CONCLUSION
Although the basis for increased "-MTrp uptake in patients with
epilepsy has not been completely elucidated and is likely to be
different depending on the etiology, available evidence suggests
that "-MTrp is a useful tracer in the presurgical evaluation of
patients with epilepsy. Depending on the nature of the epilepto-
genic lesion, "-[11C]-MTrp PET will display different specifici-
ty, with the highest shown for the dysplastic lesions of tuberous
sclerosis or cortical dysplasia. The role of "-[11C]-MTrp PET in
temporal lobe epilepsy and in cryptogenic neocortical epilepsy
remains controversial. 
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SAŽETAK
Prednosti tehnike pozitronske emisijske tomografije (PET) omoguæile su mjerenje i slikovnu dijagnostiku sinteze serotonina, trans-
port i povezivanje receptora u mozgu živoga èovjeka. Slikovna dijagnostika i patološke studije o pacijentima koji boluju od epilepsi-
je i studije nastale iz eksperimentalnih modela epilepsije pružaju dokaze da endogeni serotonin ima važnu ulogu u epileptogenezi.
Ovaj pregledni èlanak sažima prednosti alfa-metil triptofan PET vizualizacije u pacijenata koji boluju od razlièitih tipova epilepsije.
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